JPMorgan Healthcare Leaders ETF
JDOC
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 383 Madison Avenue New York NY United States of America 10179
- IPO Date
- Nov 13, 2023
- CIK
- 0001485894
- Website
- am.jpmorgan.com
- Similar Companies
- Business
- JPMorgan Healthcare Leaders ETF (JDOC) is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in equity securities of pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology, and life sciences companies identified as leaders driving innovation to address growing medical needs. The fund employs proprietary research from a global team of healthcare specialists to construct a high-conviction portfolio across all market capitalizations, with a majority focus on mid- and large-cap companies domiciled predominantly in the United States, North America (67.7%), EMEA (28.6%), and Japan (3.0%); it holds approximately 63-66 securities, with top holdings including Eli Lilly and Company (7.5%), AbbVie Inc. (6.3%), Merck & Co. Inc. (5.1%), Johnson & Johnson (4.9%), and AstraZeneca PLC (4.7%). Launched on November 1, 2023, by J.P. Morgan Asset Management, a business of JPMorgan Chase & Co., and listed on the Nasdaq Stock Market, the ETF is managed by experienced portfolio professionals including Dominic Valder (27 years) and Bartjan van Hulten (27 years), with a net expense ratio of 0.65% and assets under management of approximately $8.89 million as of November 30, 2025. In recent developments, the fund marked its inception alongside the simultaneous launch of the JPMorgan U.S. Tech Leaders ETF (JTEK) on November 2, 2023, adapting J.P. Morgan's established active healthcare strategy—previously led by a team including managing director Matt Cohen, M.D., and others with over a decade of track record—into an ETF structure to broaden investor access through low-cost, transparent vehicles emphasizing risk controls and active security selection. No major acquisitions, partnerships, funding rounds, or operational reorganizations have been reported since inception, with ongoing portfolio adjustments reflecting market conditions and the fund's focus on underappreciated growth opportunities in the global healthcare sector.